RxDoctor Payments Data

Brian Smith, MD

General Practice · Morristown, NJNPI 1538179452

Payments from drug & device makers

$3,759in general payments, 2019–2025

Across 171 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$696
  • Amarin Pharma, Inc.$594
  • Novo Nordisk$455
  • Kowa Pharmaceuticals America, Inc.$235
  • Lilly USA, LLC$125
  • plus $310 from 11 others

What the payments were for

  • Food & beverage$3,69898%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,759 in reported general payments places this provider in the 95th percentile of 2,978 general practice providers in New Jersey.

See all general practice providers in New Jersey

Medicare billing

Part B allowed, 2024
$106,227
Medicare patients
334
Services billed
977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$46,423
JanumetSitagliptin Phos/Metformin Hcl31$35,845
RybelsusSemaglutide12$16,778
XareltoRivaroxaban16$12,751
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,492
SynthroidLevothyroxine Sodium31$3,890
Olmesartan Medoxomil92$2,554
Rosuvastatin Calcium153$2,327
Atorvastatin Calcium172$1,857
Levothyroxine Sodium97$1,161
Tamsulosin Hcl34$1,062
ValacyclovirValacyclovir Hcl13$981
Metoprolol Succinate58$964
Valsartan33$946
Metformin Hcl83$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$455$16,77812 claims
AstraZenecaBreztri Aerosphere$696$7,49212 claims
AbbVieSynthroid$1,345$3,89031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,978 general practice providers in New Jersey.

Other general practice in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →